Polycystic Ovarian Syndrome - Pipeline Review, H1 2016

Detailed TOC of Polycystic Ovarian Syndrome - Pipeline Review, H1 2016

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Polycystic Ovarian Syndrome Overview 7
Therapeutics Development 8
Pipeline Products for Polycystic Ovarian Syndrome - Overview 8
Pipeline Products for Polycystic Ovarian Syndrome - Comparative Analysis 9
Polycystic Ovarian Syndrome - Therapeutics under Development by Companies 10
Polycystic Ovarian Syndrome - Therapeutics under Investigation by Universities/Institutes 11
Polycystic Ovarian Syndrome - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Polycystic Ovarian Syndrome - Products under Development by Companies 15
Polycystic Ovarian Syndrome - Products under Investigation by Universities/Institutes 16
Polycystic Ovarian Syndrome - Companies Involved in Therapeutics Development 17
Addex Therapeutics Ltd 17
Crinetics Pharmaceuticals, Inc. 18
EffRx Pharmaceuticals S.A. 19
Euroscreen S.A. 20
Merck KGaA 21
Vicore Pharma AB 22
Polycystic Ovarian Syndrome - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
C-21 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
choriogonadotropin alfa - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
ESN-364 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
JDSCR-004 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
KDT-501 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
metformin hydrochloride - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
MLE-4901 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Small Molecule to Antagonize FSH Receptor for Women's Health - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Small Molecules to Inhibit KISS-1R for Polycystic Ovarian Syndrome - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Polycystic Ovarian Syndrome - Recent Pipeline Updates 45
Polycystic Ovarian Syndrome - Dormant Projects 47
Polycystic Ovarian Syndrome - Discontinued Products 48
Polycystic Ovarian Syndrome - Product Development Milestones 49
Featured News & Press Releases 49
Apr 21, 2015: Euroscreen starts in parallel two Phase 2 clinical trials with ESN364 in UF and PCOS patients 49
Dec 08, 2014: Euroscreen Announces Positive Completion of Phase I Trial of ESN364 49
Jun 20, 2014: Euroscreen ESN364 drug candidate presented at the ICE/ENDO Meeting 50
Jun 10, 2014: EffRx Receives U.S. Orphan Drug Designation for EX404 for Treatment of Pediatric Polycystic Ovary Syndrome 50
Dec 18, 2013: Euroscreen Initiates Phase I Clinical Trial For ESN364 51
Oct 01, 2013: EffRx Receives Prestigious EUR 5.9 Million FP7 Research Grant for the Development of EX404 for Polycystic Ovary Syndrome in Pediatric Populations 51
Feb 05, 2013: Euroscreen to present ESN364 drug candidate at the 11th International Symposium on GnRH 52
Appendix 53
Methodology 53
Coverage 53
Secondary Research 53
Primary Research 53
Expert Panel Validation 53
Contact Us 53
Disclaimer 54